765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial

765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial

Bibliographic Details
Main Authors: Robert H Vonderheide, Andrew H Ko, Danny Khalil, Oliver Rosen, Robert A Wolff, James Francis, Samantha Bucktrout, Christopher R Cabanski, Silvia Boffo, Zev A Wainberg, Samik Upadhaya, Eileen M O’Reilly, Mark H O’Hara, George Fisher, Jamie Arnott, Ana Rosa Saez-Ibanez, Jay Campbell, Ute Dugan, Jill O’Donnell-Tormey
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items